6-chloroacetyl-3,4-dihydro-7-methyl-2(1H)-quinolinone | 119715-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-chloroacetyl-3,4-dihydro-7-methyl-2(1H)-quinolinone
• 英文别名: 7-Methyl-6-chloroacetyl-1,2,3,4-tetrahydro-2(1H)-quinolinone；6-(2-chloroacetyl)-7-methyl-3,4-dihydro-1H-quinolin-2-one
• CAS: 119715-36-5
• 化学式: C₁₂H₁₂ClNO₂
• 分子量: 237.686
• InChiKey: YUIQHBUVNOJERT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-chloroacetyl-3,4-dihydro-7-methyl-2(1H)-quinolinone 在 吡啶 、 sodium hydroxide 作用下， 反应 2.0h， 以88%的产率得到6-carboxy-3,4-dihydro-7-methyl-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o
• 作为产物：
  描述：

  7-methyl-3,4-dihydroquinolin-2(1H)-one 、 氯乙酰氯 在 三氯化铝 作用下， 以 二硫化碳 为溶剂， 以65%的产率得到6-chloroacetyl-3,4-dihydro-7-methyl-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o

文献信息

• Heteroaryl piperazine antipsychotic agents
  申请人：PFIZER INC.

  公开号：EP0409435B1

  公开（公告）日：1994-10-26
• US5350747A
  申请人：——

  公开号：US5350747A

  公开（公告）日：1994-09-27
• [EN] HETEROARYL PIPERAZINE ANTIPSYCHOTIC AGENTS
  申请人：PFIZER INC.

  公开号：WO1991000863A1

  公开（公告）日：1991-01-24

  (EN) Compounds of formula (I) and pharmaceutical compositions comprising them, wherein R1, Z, X, W and Y are as defined. The compounds are useful in the treatment of psychosis and anxiety.(FR) Composés de la formule (I), et compositions pharmaceutiques les comprenant, dans laquelle R1, Z, Y, W et Y ont la notation donnée dans le descriptif. Les composés sont utiles dans le traitement de la psychose et de l'anxiété.
• Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives
  作者：Shuji Teramoto、Michinori Tanaka、Hiroshi Shimizu、Takafumi Fujioka、Fujio Tabusa、Takashi Imaizumi、Kenji Yoshida、Hiroyuki Fujiki、Toyoki Mori、Takumi Sumida、Michiaki Tominaga

  DOI：10.1021/jm020597o

  日期：2003.7.1

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.